|Back to Home > Events > Media Events > Biosimilars|
May 21, 2014 to May 22, 2014
|Location||Otto-Braun-Strasse 90, 10249
|Details||Brand New for 2014:
Twice as much content - New 2-day conference on quality, CMC and analytical development of biosimilars
Unpublished data from Sandoz, Teva, Amgen, BIOCAD, Egis Pharmaceuticals and Livzon Mabpharm, Inc
Focused conference stream on clinical and non-clinical biosimilar development
Key reasons not to miss Biosimilars 2014:
Hospira and Egis Pharmaceuticals discuss the routes and launch strategy for the very first mAb biosimilar in Europe - how should you spend your resources?
Discover the latest on EU positions for interchangeability and substitution and comparison with the FDA proposals
Learn from Teva on how to carry out meaningful “fingerprint”-like analysis for effective biosimilar characterisation
Benchmark your global clinical biosimilar trials – experience from Sandoz examples with TNFa inhibitors.
Understand global development of biosimilars: with insight into Russia, CIS, Latin America and China
Price: £1,783.81 - £3,687.81
|Venue||Leonardo Royal Hotel Berlin Alexanderplatz|